{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:30:45Z","timestamp":1789842645204,"version":"4.0.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00284-022-03112-z","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:27:11Z","timestamp":1669976831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis"],"prefix":"10.1007","volume":"80","author":[{"given":"Somayeh","family":"Sedighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Yasamineh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnia","family":"Favakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Afkhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Firouzi-Amandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryoush","family":"Pahlevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahdat","family":"Poortahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7880","authenticated-orcid":false,"given":"Mehdi","family":"Dadashpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"3112_CR1","first-page":"394","volume-title":"The role of viral infections in the development of autoimmune diseases","author":"HM Hussein","year":"2019","unstructured":"Hussein HM, Rahal EA (2019) The role of viral infections in the development of autoimmune diseases. Taylor & Francis, NY, pp 394\u2013412"},{"issue":"1","key":"3112_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13(1):25\u201336","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"3112_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/ijms20040989","volume":"20","author":"E Leitzen","year":"2019","unstructured":"Leitzen E et al (2019) Comparison of reported spinal cord lesions in progressive multiple sclerosis with theiler\u2019s murine encephalomyelitis virus induced demyelinating disease. Int J Mol Sci 20(4):989","journal-title":"Int J Mol Sci"},{"key":"3112_CR4","first-page":"269","volume":"8","author":"R Mechelli","year":"2021","unstructured":"Mechelli R et al (2021) Viruses and neuroinflammation in multiple sclerosis. Neuroimmunology and Neuroinflammation 8:269\u2013283","journal-title":"Neuroimmunology and Neuroinflammation"},{"key":"3112_CR5","first-page":"3315","volume":"2020","author":"G Houen","year":"2020","unstructured":"Houen G, Trier NH, Frederiksen JL (2020) Epstein-Barr virus and multiple sclerosis. Front Immunol 2020:3315","journal-title":"Front Immunol"},{"issue":"1","key":"3112_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-00645-3","volume":"7","author":"M Vanheusden","year":"2017","unstructured":"Vanheusden M et al (2017) Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation. Sci Rep 7(1):1\u201311","journal-title":"Sci Rep"},{"issue":"1","key":"3112_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jcm8010003","volume":"8","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Skinner DD, Lane TE (2018) Innate immune responses and Viral-Induced neurologic disease. J Clin Med 8(1):3","journal-title":"J Clin Med"},{"key":"3112_CR8","doi-asserted-by":"publisher","first-page":"103318","DOI":"10.1016\/j.msard.2021.103318","volume":"57","author":"T Latifi","year":"2021","unstructured":"Latifi T, Zebardast A, Marashi SM (2021) The role of human endogenous retroviruses (HERVs) in multiple sclerosis and the plausible interplay between HERVs, Epstein-Barr virus infection, and vitamin D. Mult Scler Relat Disorders 57:103318\u2013103318","journal-title":"Mult Scler Relat Disorders"},{"issue":"3","key":"3112_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","volume":"26","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A et al (2020) Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol Med 26(3):296\u2013310","journal-title":"Trends Mol Med"},{"issue":"7","key":"3112_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458518823940","volume":"25","author":"M Marrodan","year":"2019","unstructured":"Marrodan M et al (2019) The role of infections in multiple sclerosis. Mult Scler J 25(7):891\u2013901","journal-title":"Mult Scler J"},{"key":"3112_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jneuroim.2017.04.004","volume":"309","author":"S Karampoor","year":"2017","unstructured":"Karampoor S et al (2017) Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: a population-based study. J Neuroimmunol 309:4\u20136","journal-title":"J Neuroimmunol"},{"key":"3112_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddmod.2020.02.003","volume":"32","author":"D Donati","year":"2020","unstructured":"Donati D (2020) Viral infections and multiple sclerosis. Drug Discov Today Dis Model 32:27\u201333","journal-title":"Drug Discov Today Dis Model"},{"key":"3112_CR13","doi-asserted-by":"publisher","first-page":"105657","DOI":"10.1016\/j.micpath.2022.105657","volume":"8","author":"O Gholizadeh","year":"2022","unstructured":"Gholizadeh O et al (2022) Recent advances in treatment Crimean-Congo hemorrhagic fever virus: a concise overview. Microb Pathog 8:105657","journal-title":"Microb Pathog"},{"issue":"10","key":"3112_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/medicines8100055","volume":"8","author":"L Freire-de-Lima","year":"2021","unstructured":"Freire-de-Lima L et al (2021) Autoimmune disorders & COVID-19. Medicines 8(10):55\u201355","journal-title":"Medicines"},{"issue":"3","key":"3112_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13337-020-00592-0","volume":"31","author":"M Keikha","year":"2020","unstructured":"Keikha M et al (2020) HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease 31(3):235\u2013240","journal-title":"Virusdisease"},{"key":"3112_CR16","doi-asserted-by":"publisher","first-page":"102967","DOI":"10.1016\/j.jddst.2021.102967","volume":"67","author":"B Hashemi","year":"2021","unstructured":"Hashemi B et al (2021) Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. Journal of Drug Delivery Science and Technology 67:102967","journal-title":"Journal of Drug Delivery Science and Technology"},{"issue":"2","key":"3112_CR17","doi-asserted-by":"publisher","first-page":"e14415","DOI":"10.1111\/dme.14415","volume":"38","author":"M Eslami","year":"2021","unstructured":"Eslami M et al (2021) Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders. Diabet Med 38(2):e14415","journal-title":"Diabet Med"},{"issue":"1","key":"3112_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1352458517737392","volume":"24","author":"EC Leibovitch","year":"2018","unstructured":"Leibovitch EC, Jacobson S (2018) Viruses in chronic progressive neurologic disease. Mult Scler J 24(1):48\u201352","journal-title":"Mult Scler J"},{"key":"3112_CR19","doi-asserted-by":"publisher","first-page":"102633","DOI":"10.1016\/j.msard.2020.102633","volume":"47","author":"L Xu","year":"2021","unstructured":"Xu L et al (2021) Positive association of herpes simplex virus-IgG with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disorders 47:102633","journal-title":"Mult Scler Relat Disorders"},{"issue":"8","key":"3112_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/NEN.0b013e318180e631","volume":"67","author":"L Del Valle","year":"2008","unstructured":"Del Valle L, White MK, Khalili K (2008) Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol 67(8):729\u2013740","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"3112_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1073\/pnas.75.3.1126","volume":"75","author":"G Meneguzzi","year":"1978","unstructured":"Meneguzzi G et al (1978) Minichromosome from BK virus as a template for transcription in vitro. Proc Natl Acad Sci 75(3):1126\u20131130","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"3112_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/fvl.10.12","volume":"5","author":"AS Sariba\u015f","year":"2010","unstructured":"Sariba\u015f AS et al (2010) JC virus-induced progressive multifocal leukoencephalopathy. Futur Virol 5(3):313\u2013323","journal-title":"Futur Virol"},{"key":"3112_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.coi.2020.01.004","volume":"62","author":"E Jouanguy","year":"2020","unstructured":"Jouanguy E et al (2020) Human inborn errors of immunity to herpes viruses. Curr Opin Immunol 62:106\u2013122","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"3112_CR24","doi-asserted-by":"publisher","first-page":"e01593","DOI":"10.1128\/JVI.01593-18","volume":"93","author":"V Majerciak","year":"2019","unstructured":"Majerciak V et al (2019) A genome-wide Epstein-Barr virus polyadenylation map and its antisense RNA to EBNA. J Virol 93(2):e01593-e1618","journal-title":"J Virol"},{"issue":"6","key":"3112_CR25","doi-asserted-by":"publisher","first-page":"e1009618","DOI":"10.1371\/journal.ppat.1009618","volume":"17","author":"SS Soldan","year":"2021","unstructured":"Soldan SS et al (2021) Epigenetic plasticity enables CNS-trafficking of EBV-infected B lymphocytes. PLoS Pathog 17(6):e1009618","journal-title":"PLoS Pathog"},{"key":"3112_CR26","doi-asserted-by":"publisher","first-page":"103572","DOI":"10.1016\/j.ebiom.2021.103572","volume":"71","author":"JT Keane","year":"2021","unstructured":"Keane JT et al (2021) The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype. EBioMedicine 71:103572\u2013103572","journal-title":"EBioMedicine"},{"issue":"3","key":"3112_CR27","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/NXI.0000000000000308","volume":"4","author":"J Endriz","year":"2017","unstructured":"Endriz J, Ho PP, Steinman L (2017) Time correlation between mononucleosis and initial symptoms of MS. Neurol-Neuroimmunol Neuroinflam 4(3):e308","journal-title":"Neurol-Neuroimmunol Neuroinflam"},{"issue":"1","key":"3112_CR28","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1038\/cti.2016.87","volume":"6","author":"MP Pender","year":"2017","unstructured":"Pender MP et al (2017) Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin Trans Immunol 6(1):e126","journal-title":"Clin Trans Immunol"},{"key":"3112_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-22822-8_6","volume":"1","author":"W Hammerschmidt","year":"2015","unstructured":"Hammerschmidt W (2015) The epigenetic life cycle of Epstein-Barr virus. Epstein Barr Virus 1:103\u2013117","journal-title":"Epstein Barr Virus"},{"issue":"4","key":"3112_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/imm.12808","volume":"152","author":"MT Cencioni","year":"2017","unstructured":"Cencioni MT et al (2017) Programmed death 1 is highly expressed on CD 8+ CD 57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. Immunology 152(4):660\u2013676","journal-title":"Immunology"},{"key":"3112_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/imr.12791","volume":"291","author":"S Latour","year":"2019","unstructured":"Latour S, Fischer A (2019) Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. Immunol Rev 291:174\u2013189","journal-title":"Immunol Rev"},{"issue":"5","key":"3112_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/jnnp.2008.161018","volume":"80","author":"MP Pender","year":"2009","unstructured":"Pender MP et al (2009) Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 80(5):498\u2013505","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"24","key":"3112_CR33","doi-asserted-by":"publisher","first-page":"e00980","DOI":"10.1128\/JVI.00980-19","volume":"93","author":"B Serafini","year":"2019","unstructured":"Serafini B et al (2019) Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J Virol 93(24):e00980-e1019","journal-title":"J Virol"},{"issue":"42","key":"3112_CR34","doi-asserted-by":"publisher","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","volume":"113","author":"M Albanese","year":"2016","unstructured":"Albanese M et al (2016) Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci 113(42):E6467\u2013E6475","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"3112_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/microorganisms7060183","volume":"7","author":"S Jangra","year":"2019","unstructured":"Jangra S et al (2019) Epstein-Barr virus and innate immunity: Friends or foes? Microorganisms 7(6):183","journal-title":"Microorganisms"},{"issue":"1","key":"3112_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I et al (2018) Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell 175(1):85\u2013100","journal-title":"Cell"},{"issue":"2","key":"3112_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.15252\/emmm.201708292","volume":"10","author":"S Winter","year":"2018","unstructured":"Winter S et al (2018) Loss of RASGRP 1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility. EMBO Mol Med 10(2):188\u2013199","journal-title":"EMBO Mol Med"},{"issue":"5","key":"3112_CR38","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.celrep.2017.01.020","volume":"18","author":"F Wanke","year":"2017","unstructured":"Wanke F et al (2017) EBI2 is highly expressed in multiple sclerosis lesions and promotes early CNS migration of encephalitogenic CD4 T cells. Cell Rep 18(5):1270\u20131284","journal-title":"Cell Rep"},{"key":"3112_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2018.01.029","volume":"133","author":"A Rutkowska","year":"2018","unstructured":"Rutkowska A et al (2018) EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes. Neuropharmacology 133:121\u2013128","journal-title":"Neuropharmacology"},{"issue":"1","key":"3112_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.celrep.2016.12.006","volume":"18","author":"AS Clottu","year":"2017","unstructured":"Clottu AS et al (2017) EBI2 expression and function: robust in memory lymphocytes and increased by natalizumab in multiple sclerosis. Cell Rep 18(1):213\u2013224","journal-title":"Cell Rep"},{"key":"3112_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.06.023","volume":"182","author":"X Liu","year":"2020","unstructured":"Liu X et al (2020) Human virus transcriptional regulators. Cell 182:24\u201337","journal-title":"Cell"},{"issue":"1","key":"3112_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-019-0640-z","volume":"11","author":"A Afrasiabi","year":"2019","unstructured":"Afrasiabi A et al (2019) Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. Genome medicine 11(1):1\u201313","journal-title":"Genome medicine"},{"issue":"10","key":"3112_CR43","doi-asserted-by":"publisher","first-page":"e1006664","DOI":"10.1371\/journal.ppat.1006664","volume":"13","author":"LV Glaser","year":"2017","unstructured":"Glaser LV et al (2017) EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes in B cells. PLoS Pathog 13(10):e1006664","journal-title":"PLoS Pathog"},{"issue":"1","key":"3112_CR44","first-page":"205521731990129","volume":"6","author":"CS Simonsen","year":"2020","unstructured":"Simonsen CS et al (2020) The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Mult Scler J-Exp Trans Clin 6(1):2055217319901291\u20132055217319901291","journal-title":"Mult Scler J-Exp Trans Clin"},{"issue":"1","key":"3112_CR45","first-page":"205521731983666","volume":"5","author":"N Makhani","year":"2019","unstructured":"Makhani N et al (2019) Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. Mult Scler J-Exp Trans Clin 5(1):2055217319836664","journal-title":"Mult Scler J-Exp Trans Clin"},{"issue":"4","key":"3112_CR46","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awy006","volume":"141","author":"G Arrambide","year":"2018","unstructured":"Arrambide G et al (2018) The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain 141(4):1075\u20131084","journal-title":"Brain"},{"issue":"2","key":"3112_CR47","doi-asserted-by":"publisher","first-page":"e0192109","DOI":"10.1371\/journal.pone.0192109","volume":"13","author":"A Hassani","year":"2018","unstructured":"Hassani A et al (2018) Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS ONE 13(2):e0192109","journal-title":"PLoS ONE"},{"issue":"5\u20136","key":"3112_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000496402","volume":"80","author":"A Czarnowska","year":"2018","unstructured":"Czarnowska A et al (2018) Herpesviridae seropositivity in patients with multiple sclerosis: first polish study. Eur Neurol 80(5\u20136):229\u2013235","journal-title":"Eur Neurol"},{"issue":"4","key":"3112_CR49","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1212\/NXI.0000000000000466","volume":"5","author":"MA Moreno","year":"2018","unstructured":"Moreno MA et al (2018) Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol-Neuroimmunol Neuroinflamm 5(4):e466","journal-title":"Neurol-Neuroimmunol Neuroinflamm"},{"issue":"3","key":"3112_CR50","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jinf.2019.10.017","volume":"80","author":"PA Maple","year":"2020","unstructured":"Maple PA et al (2020) A different response to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls. J Infect 80(3):320\u2013325","journal-title":"J Infect"},{"issue":"1","key":"3112_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-017-1049-5","volume":"15","author":"C Veroni","year":"2018","unstructured":"Veroni C et al (2018) Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J Neuroinflammation 15(1):1\u201319","journal-title":"J Neuroinflammation"},{"issue":"11","key":"3112_CR52","doi-asserted-by":"publisher","first-page":"a032003","DOI":"10.1101\/cshperspect.a032003","volume":"8","author":"D Jakimovski","year":"2018","unstructured":"Jakimovski D et al (2018) Interferon \u03b2 for multiple sclerosis. Cold Spring Harb Perspect Med 8(11):a032003","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3112_CR53","doi-asserted-by":"publisher","first-page":"101388","DOI":"10.1016\/j.msard.2019.101388","volume":"36","author":"R Zivadinov","year":"2019","unstructured":"Zivadinov R et al (2019) Teriflunomide\u2019s effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Mult Scler Relat Disorders 36:101388","journal-title":"Mult Scler Relat Disorders"},{"issue":"1","key":"3112_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0415-2","volume":"13","author":"JG Ogembo","year":"2015","unstructured":"Ogembo JG et al (2015) A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J Transl Med 13(1):1\u201315","journal-title":"J Transl Med"},{"key":"3112_CR55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/978-3-319-22834-1_16","volume":"2","author":"C Smith","year":"2015","unstructured":"Smith C, Khanna R (2015) The development of prophylactic and therapeutic EBV vaccines. Epstein Barr Virus 2:455\u2013473","journal-title":"Epstein Barr Virus"},{"issue":"8","key":"3112_CR56","doi-asserted-by":"publisher","first-page":"12415","DOI":"10.1002\/jcp.28076","volume":"234","author":"M Eslami","year":"2019","unstructured":"Eslami M et al (2019) Mycobacterium avium paratuberculosis and Mycobacterium avium complex and related subspecies as causative agents of zoonotic and occupational diseases. J Cell Physiol 234(8):12415\u201312421","journal-title":"J Cell Physiol"},{"key":"3112_CR57","doi-asserted-by":"publisher","first-page":"175628641877302","DOI":"10.1177\/1756286418773025","volume":"11","author":"P Mulero","year":"2018","unstructured":"Mulero P, Midaglia L, Montalban X (2018) Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 11:1756286418773025","journal-title":"Ther Adv Neurol Disord"},{"key":"3112_CR58","doi-asserted-by":"publisher","first-page":"577313","DOI":"10.1016\/j.jneuroim.2020.577313","volume":"346","author":"H Keyvani","year":"2020","unstructured":"Keyvani H et al (2020) The role of human herpesvirus-6 and inflammatory markers in the pathogenesis of multiple sclerosis. J Neuroimmunol 346:577313","journal-title":"J Neuroimmunol"},{"issue":"6","key":"3112_CR59","doi-asserted-by":"publisher","first-page":"e12984","DOI":"10.1111\/sji.12984","volume":"92","author":"N Dunn","year":"2020","unstructured":"Dunn N, Kharlamova N, Fogdell-Hahn A (2020) The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy. Scand J Immunol 92(6):e12984","journal-title":"Scand J Immunol"},{"issue":"1","key":"3112_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-018-4604-2","volume":"19","author":"AL Greninger","year":"2018","unstructured":"Greninger AL et al (2018) Comparative genomic, transcriptomic, and proteomic reannotation of human herpesvirus 6. BMC Genomics 19(1):1\u201317","journal-title":"BMC Genomics"},{"key":"3112_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02715","author":"E Engdahl","year":"2019","unstructured":"Engdahl E et al (2019) Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02715","journal-title":"Front Immunol"},{"issue":"22","key":"3112_CR62","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1073\/pnas.1305187110","volume":"110","author":"H Tang","year":"2013","unstructured":"Tang H et al (2013) CD134 is a cellular receptor specific for human herpesvirus-6B entry. Proc Natl Acad Sci 110(22):9096\u20139099","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"3112_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-017-0719-3","volume":"14","author":"W Fierz","year":"2017","unstructured":"Fierz W (2017) Multiple sclerosis: an example of pathogenic viral interaction? Virology journal 14(1):1\u20135","journal-title":"Virology journal"},{"issue":"2","key":"3112_CR64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11481-007-9084-0","volume":"3","author":"J Fotheringham","year":"2008","unstructured":"Fotheringham J et al (2008) Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes. J Neuroimmune Pharmacol 3(2):105\u2013116","journal-title":"J Neuroimmune Pharmacol"},{"issue":"8","key":"3112_CR65","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1177\/1352458517704711","volume":"23","author":"E Morandi","year":"2017","unstructured":"Morandi E et al (2017) Human endogenous retroviruses and multiple sclerosis: causation, association, or after-effect? Mult Scler J 23(8):1050\u20131055","journal-title":"Mult Scler J"},{"issue":"4","key":"3112_CR66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.molmed.2018.02.007","volume":"24","author":"P K\u00fcry","year":"2018","unstructured":"K\u00fcry P et al (2018) Human endogenous retroviruses in neurological diseases. Trends Mol Med 24(4):379\u2013394","journal-title":"Trends Mol Med"},{"key":"3112_CR67","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fpsyt.2018.00422","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Huang J, Zhu F (2018) Human endogenous retroviral envelope protein syncytin-1 and inflammatory abnormalities in neuropsychological diseases. Front Psych 9:422","journal-title":"Front Psych"},{"issue":"1","key":"3112_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1352458517737370","volume":"24","author":"A Dolei","year":"2018","unstructured":"Dolei A (2018) The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis. Mult Scler J 24(1):42\u201347","journal-title":"Mult Scler J"},{"issue":"11","key":"3112_CR69","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/intimm\/dxv025","volume":"27","author":"A Duperray","year":"2015","unstructured":"Duperray A et al (2015) Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. Int Immunol 27(11):545\u2013553","journal-title":"Int Immunol"},{"key":"3112_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jneuroim.2015.12.006","volume":"291","author":"A Madeira","year":"2016","unstructured":"Madeira A et al (2016) MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: relevance of GNbAC1 in multiple sclerosis treatment. J Neuroimmunol 291:29\u201338","journal-title":"J Neuroimmunol"},{"issue":"6","key":"3112_CR71","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.3390\/v6062242","volume":"6","author":"PJ Hanley","year":"2014","unstructured":"Hanley PJ, Bollard CM (2014) Controlling cytomegalovirus: helping the immune system take the lead. Viruses 6(6):2242\u20132258","journal-title":"Viruses"},{"issue":"1","key":"3112_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3233\/HAB-170317","volume":"26","author":"MA Salim","year":"2017","unstructured":"Salim MA et al (2017) Determining the IgM and IgG antibody titer against CMV and helicobacter pylori in the serum of multiple sclerosis patients comparing to the control group in Hamadan. Hum Antibodies 26(1):23\u201328","journal-title":"Hum Antibodies"},{"issue":"5","key":"3112_CR73","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.28084","volume":"35","author":"A Lippi","year":"2020","unstructured":"Lippi A et al (2020) SARS-CoV-2: at the crossroad between aging and neurodegeneration. Mov Disord 35(5):716","journal-title":"Mov Disord"},{"key":"3112_CR74","doi-asserted-by":"publisher","first-page":"121878","DOI":"10.1016\/j.ijpharm.2022.121878","volume":"624","author":"S Yasamineh","year":"2022","unstructured":"Yasamineh S et al (2022) A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. Int J Pharm 624:121878","journal-title":"Int J Pharm"},{"issue":"12","key":"3112_CR75","doi-asserted-by":"publisher","first-page":"9133","DOI":"10.1002\/jcp.29785","volume":"235","author":"B Yousefi","year":"2020","unstructured":"Yousefi B et al (2020) A global treatments for coronaviruses including COVID-19. J Cell Physiol 235(12):9133\u20139142","journal-title":"J Cell Physiol"},{"issue":"2","key":"3112_CR76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00415-020-10070-8","volume":"268","author":"L Ferini-Strambi","year":"2021","unstructured":"Ferini-Strambi L, Salsone M (2021) COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol 268(2):409\u2013419","journal-title":"J Neurol"},{"issue":"3","key":"3112_CR77","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nrleng.2020.03.002","volume":"35","author":"J Mat\u00edas-Guiu","year":"2020","unstructured":"Mat\u00edas-Guiu J et al (2020) Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurolog\u00eda (English Edition) 35(3):170\u2013175","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"1","key":"3112_CR78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13287-022-02944-7","volume":"13","author":"S Yasamineh","year":"2022","unstructured":"Yasamineh S et al (2022) Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19. Stem Cell Res Ther 13(1):257","journal-title":"Stem Cell Res Ther"},{"key":"3112_CR79","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbi.2019.12.011","volume":"87","author":"AI Rodriguez-Perez","year":"2020","unstructured":"Rodriguez-Perez AI et al (2020) Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. Brain Behav Immun 87:256\u2013271","journal-title":"Brain Behav Immun"},{"issue":"3","key":"3112_CR80","doi-asserted-by":"publisher","first-page":"e560","DOI":"10.20883\/medical.e560","volume":"90","author":"D Kova\u010di\u0107","year":"2021","unstructured":"Kova\u010di\u0107 D, Jotanovi\u0107 J, Lakovi\u0107 J (2021) The possible role of molecular mimicry in SARS-CoV-2-mediated autoimmunity: an immunobiochemical basis. J Med Sci 90(3):e560\u2013e560","journal-title":"J Med Sci"},{"issue":"1","key":"3112_CR81","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1097\/MRM.0000000000000265","volume":"33","author":"B Yousefi","year":"2022","unstructured":"Yousefi B, Eslami M (2022) Genetic and structure of novel coronavirus COVID-19 and molecular mechanisms in the pathogenicity of coronaviruses. Rev Med Microb 33(1):e180\u2013e188","journal-title":"Rev Med Microb"},{"issue":"2","key":"3112_CR82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/2045-9912.325989","volume":"12","author":"B Yousefi","year":"2022","unstructured":"Yousefi B et al (2022) Potential therapeutic effect of oxygen-ozone in controlling of COVID-19 disease. Med Gas Res 12(2):33","journal-title":"Med Gas Res"},{"issue":"3","key":"3112_CR83","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaut.2008.04.017","volume":"31","author":"V Dardalhon","year":"2008","unstructured":"Dardalhon V et al (2008) Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 31(3):252\u2013256","journal-title":"J Autoimmun"},{"issue":"5","key":"3112_CR84","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00415-020-09822-3","volume":"267","author":"M Willis","year":"2020","unstructured":"Willis M, Robertson N (2020) Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19\/SARS-CoV-2. J Neurol 267(5):1567\u20131569","journal-title":"J Neurol"},{"issue":"9","key":"3112_CR85","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre C et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77(9):1079\u20131088","journal-title":"JAMA Neurol"},{"issue":"1","key":"3112_CR86","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12951-022-01625-0","volume":"20","author":"S Yasamineh","year":"2022","unstructured":"Yasamineh S et al (2022) An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. Journal of Nanobiotechnology 20(1):440","journal-title":"Journal of Nanobiotechnology"},{"issue":"4","key":"3112_CR87","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1212\/NXI.0000000000000761","volume":"7","author":"JR Berger","year":"2020","unstructured":"Berger JR, Brandstadter R, Bar-Or A (2020) COVID-19 and MS disease-modifying therapies. Neurol-Neuroimmunol Neuroinflamm 7(4):e761","journal-title":"Neurol-Neuroimmunol Neuroinflamm"},{"key":"3112_CR88","volume-title":"COVID-19 coinfection in patients with active tuberculosis: first case-report in Iran","author":"NG Fard","year":"2021","unstructured":"Fard NG et al (2021) COVID-19 coinfection in patients with active tuberculosis: first case-report in Iran. Authorea Preprints"},{"key":"3112_CR89","doi-asserted-by":"publisher","first-page":"102174","DOI":"10.1016\/j.msard.2020.102174","volume":"43","author":"D Baker","year":"2020","unstructured":"Baker D et al (2020) The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disorders 43:102174","journal-title":"Mult Scler Relat Disorders"},{"key":"3112_CR90","doi-asserted-by":"publisher","first-page":"577283","DOI":"10.1016\/j.jneuroim.2020.577283","volume":"345","author":"MK Racke","year":"2020","unstructured":"Racke MK, Newsome SD (2020) Multiple sclerosis and COVID-19: a great opportunity for databases promoting research and collaboration. J Neuroimmunol 345:577283","journal-title":"J Neuroimmunol"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-022-03112-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-022-03112-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-022-03112-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:24:34Z","timestamp":1744208674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-022-03112-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3112"],"URL":"https:\/\/doi.org\/10.1007\/s00284-022-03112-z","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"15"}}